Studio sull'efficacia e la sicurezza PF-06741086 in partecipanti adulti e adolescenti con emofilia A grave o emofilia B da moderatamente grave a grave
Uno studio in aperto su adolescenti e adulti gravi (attività del fattore di coagulazione
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Fase
Fase
- Fase 3
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Pfizer CT.gov Call Center
- Numero di telefono: 1-800-718-1021
- Email: ClinicalTrials.gov_Inquiries@pfizer.com
Luoghi di studio
-
-
-
Jeddah, Arabia Saudita, 21589
- King AbdulAziz University Hospital
-
Riyadh, Arabia Saudita
- King Faisal Specialist Hospital & Research Center
-
-
-
-
-
Sofia, Bulgaria, 1756
- National Specialized Hospital for the Active Treatment of Hematological Diseases - EAD, Sofia
-
Stara Zagora, Bulgaria, 6003
- UMHAT "Prof.Dr. Stoyan Kirkovich"
-
-
-
-
Ontario
-
Hamilton, Ontario, Canada, L8S 4K1
- McMaster University
-
Hamilton, Ontario, Canada, L8S 4K1
- McMaster Children's Hospital
-
Hamilton, Ontario, Canada, L8N 3Z5
- McMaster University Medical Centre - Hamilton Health Sciences
-
Toronto, Ontario, Canada, M5G 1X8
- The Hospital for Sick Children
-
-
-
-
-
Beijing, Cina, 100045
- Beijing Children's Hospital, Capital Medical University
-
-
Guangdong
-
Guangzhou, Guangdong, Cina, 510515
- Nanfang Hospital, Southern Medical University
-
-
Guizhou
-
Guiyang, Guizhou, Cina, 550004
- The Affiliated Hospital of Guizhou Medical University
-
-
Jiangxi
-
Nanchang, Jiangxi, Cina, 306113
- Jiangxi Provincial People's Hospital
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, Cina, 300020
- Institute of Hematology, Chinese Academy of Medical Sciences
-
-
-
-
-
Daegu, Corea del Sud, 41944
- Kyungpook National University Hospital
-
Seoul, Corea del Sud, 03722
- Severance Hospital, Yonsei University Health System
-
Seoul, Corea del Sud, 05278
- Kyung Hee University Hospital at Gangdong
-
-
-
-
-
Zagreb, Croazia, 10000
- Klinicki bolnicki centar Zagreb
-
-
-
-
-
Paris, Francia, 75015
- Hôpital Necker Enfants malades
-
-
-
-
-
Hiroshima, Giappone, 734-8551
- Hiroshima University Hospital
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Giappone, 466-8560
- Nagoya University Hospital - Transfusion Medicine
-
-
Hokkaido
-
Sapporo, Hokkaido, Giappone, 004-0041
- Sapporo Tokushukai Hospital
-
-
Saitama
-
Iruma-gun, Saitama, Giappone, 350-0495
- Saitama Medical University Hospital
-
-
-
-
-
Hong Kong, Hong Kong
- Queen Mary Hospital
-
Hong Kong, Hong Kong
- Prince of Wales Hospital
-
-
-
-
Gujarat
-
Surat, Gujarat, India, 395002
- Nirmal Hospital Pvt, Ltd
-
-
Maharashtra
-
Pune, Maharashtra, India, 411004
- Sahyadri Super Speciality Hospital
-
Pune, Maharashtra, India, 411004
- Sahyadri Clinical Research And Development Center
-
-
Tamil Nadu
-
Vellore, Tamil Nadu, India, 632004
- Christian Medical College
-
-
-
-
-
Perugia, Italia, 06156
- Università degli Studi di Perugia, Azienda Ospedaliera di Perugia, Ospedale Santa Maria della
-
-
Milan
-
Milan, Milan, Italia, 20122
- Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
-
-
RM
-
Roma, RM, Italia, 00161
- Università degli Studi di Roma "Sapienza"-Policlinico Umberto I
-
-
-
-
Nuevo León
-
Monterrey, Nuevo León, Messico, 64460
- Hospital Universitario "Dr Jose Eleuterio Gonzalez"
-
-
Yucatán
-
Mérida, Yucatán, Messico, 97130
- Centro Multidisciplinario para el Desarrollo Especializado de la Inv. Clínica en Yucatán, S.C.P.
-
-
-
-
-
Muscat, Oman, 123
- Sultan Qaboos University Hospital
-
-
-
-
-
Samara, Russia, 443079
- FGBOU VO "Samara State Medical University" of MoH of Russia
-
-
-
-
-
Belgrade, Serbia, 11000
- Clinical Center of Serbia
-
Belgrade, Serbia, 11000
- Institute for Mother and Child healthcare "Dr Vukan Cupic"
-
Kragujevac, Serbia, 34000
- Clinical Center Kragujevac
-
Niš, Serbia, 18000
- Clinical Center Niš
-
-
-
-
-
A Coruña, Spagna, 15006
- Hospital Universitario A Coruna
-
Barcelona, Spagna, 08035
- Hospital Universitario Vall d´Hebron
-
Madrid, Spagna, 28046
- Hospital Universitario La Paz
-
Salamanca, Spagna, 37007
- Hospital Universitario De Salamanca
-
Zaragoza, Spagna, 50009
- Hospital Universitario Miguel Servet
-
-
-
-
Florida
-
Tampa, Florida, Stati Uniti, 33612
- USF Health Morsani Center for Advanced Healthcare
-
-
Iowa
-
Iowa City, Iowa, Stati Uniti, 52242
- University of Iowa
-
-
New York
-
New Hyde Park, New York, Stati Uniti, 11040
- Northwell Health HTC
-
-
Washington
-
Seattle, Washington, Stati Uniti, 98101
- Washington Institute for Coagulation
-
-
-
-
Gauteng
-
Johannesburg, Gauteng, Sud Africa, 2193
- Charlotte Maxeke Johannesburg Academic Hospital
-
-
-
-
-
Taichung, Taiwan, 40705
- Taichung Veterans General Hospital
-
-
Changhua County
-
Changhua, Changhua County, Taiwan, 500
- Changhua Christian Hospital
-
-
-
-
-
Adana, Turchia (Türkiye), 01130
- Acibadem Adana Hospital
-
Ankara, Turchia (Türkiye), 06230
- Hacettepe University Medical Faculty
-
Ankara, Turchia (Türkiye), 06500
- Gazi University Health Research and Practice Center Gazi Hospital
-
Antalya, Turchia (Türkiye), 07060
- Akdeniz University Medical Faculty
-
Gaziantep, Turchia (Türkiye), 27310
- Gaziantep University Sahinbey Research and Training Hospital
-
Istanbul, Turchia (Türkiye), 34093
- Istanbul University Oncology Institute
-
Izmir, Turchia (Türkiye), 35040
- Ege University Medical Faculty
-
Izmir, Turchia (Türkiye), 35210
- Dr. Behcet Uz Child Diseases Surgery Education and Research Hospital
-
Kayseri, Turchia (Türkiye), 38039
- Erciyes University Medical Faculty
-
Samsun, Turchia (Türkiye), 55280
- Ondokuz Mayıs University Medical Faculty
-
Trabzon, Turchia (Türkiye), 61080
- Karadeniz Technical University Medical Faculty
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Descrizione
Criterio di inclusione
- - Partecipanti con diagnosi di emofilia A grave o emofilia B da moderatamente grave a grave con un peso minimo di 35 kg allo screening.
- Partecipante o rappresentante legalmente autorizzato, o badante del partecipante in grado di fornire il consenso informato firmato (o il consenso minore, se applicabile).
I partecipanti che sono iscritti alla coorte dei non inibitori devono inoltre soddisfare i seguenti criteri:
- Nessuna storia rilevabile o documentata di inibitori
- - Partecipanti alla profilassi di routine con FVIII/FIX che hanno dimostrato almeno l'80% di conformità con il regime di profilassi programmato nei 6 mesi precedenti l'arruolamento e sono disposti a continuare a ricevere il trattamento di profilassi di routine con la sostituzione di FVIII/FIX durante la fase di osservazione.
- - Partecipanti con regime di trattamento su richiesta con ≥6 episodi di sanguinamento acuto (spontaneo o traumatico) che hanno richiesto l'infusione di fattori della coagulazione durante il periodo di 6 mesi prima dell'arruolamento e disposti a continuare a ricevere il trattamento su richiesta durante la fase di osservazione.
I partecipanti iscritti alla Coorte degli inibitori devono inoltre soddisfare i seguenti criteri:
- Documentazione dell'attuale inibitore ad alto titolo (≥5 BU/mL) o attuale inibitore a basso titolo (<5 BU/mL) refrattario alla sostituzione di FVIII o FIX e con recupero di FVIII o FIX <60% del previsto nei 6 mesi precedenti l'arruolamento in la fase osservativa
- Partecipanti con emofilia A con regime di trattamento al bisogno con ≥6 episodi emorragici o partecipanti con emofilia B con ≥4 episodi emorragici (spontanei o traumatici) che richiedono un trattamento con fattore di bypass durante i 6 mesi precedenti l'arruolamento nella fase osservazionale e disposti a continuare a ricevere -domanda di trattamento durante la Fase Osservazionale.
- - Partecipanti che hanno documentato inibitori durante la terapia di sostituzione del fattore ma che non soddisfano i criteri di inibizione quantitativa descritti nel punto precedente al momento dello screening (p. es., partecipante con un inibitore ad alto titolo precedentemente documentato (≥5 BU/mL) e la cui condizione preclude il re-challenge con sostituzione di FVIII o FIX) può essere considerata per l'ammissibilità caso per caso previo accordo con il Pfizer Medical Monitor
- I partecipanti che soddisfano i criteri di sanguinamento sopra indicati e che seguono una profilassi di routine (definita come trattamento mediante iniezione endovenosa di fattore di bypass per prevenire il sanguinamento) e hanno dimostrato almeno l'80% di conformità al regime di profilassi programmato durante i 6 mesi precedenti l'arruolamento, possono essere considerato per l'ammissibilità caso per caso con discussione e accordo da parte del monitor medico Pfizer.
Criteri di esclusione
- Trattamento precedente o in corso per e/o anamnesi di malattie coronariche, trombosi venosa o arteriosa o malattia ischemica
- Procedura chirurgica pianificata nota durante il periodo di studio pianificato.
- Difetto emostatico noto diverso dall'emofilia A o B.
- Funzionalità renale o epatica anomala
- Attuale malattia epatica o biliare instabile
- Parametri ematologici anormali
- Altre condizioni mediche o psichiatriche acute o croniche o anomalie di laboratorio che possono aumentare il rischio associato alla partecipazione allo studio o alla somministrazione del prodotto sperimentale o possono interferire con l'interpretazione dei risultati dello studio e, a giudizio dello sperimentatore,
- Profilassi di routine in corso con agenti bypassanti o terapia sostitutiva senza fattore di coagulazione o qualsiasi trattamento precedente con un prodotto di terapia genica per il trattamento dell'emofilia (i partecipanti trattati con profilassi utilizzando agenti bypassanti o che hanno ricevuto un precedente trattamento con prodotti senza fattore possono essere considerato caso per caso).
Terapia regolare e concomitante con farmaci immunomodulatori
- Uso in corso o pianificato dell'induzione della tolleranza immunitaria durante la fase di osservazione o la fase di trattamento attivo, o la profilassi con sostituzione di FVIII o FIX in qualsiasi momento dopo l'inizio del trattamento con l'intervento dello studio durante la fase di trattamento attivo
- Precedente esposizione a PF 06741086 durante la partecipazione agli studi B7841002 e B7841003.
- - Partecipazione ad altri studi che coinvolgono farmaci sperimentali o vaccini sperimentali entro 30 giorni (o come determinato dai requisiti locali) o 5 emivite prima dell'ingresso nello studio e/o durante la partecipazione allo studio.
- Conta delle cellule CD4 ≤200/uL se positivo al virus dell'immunodeficienza umana (HIV).
- Screening ECG che dimostra anomalie clinicamente rilevanti che possono influenzare la sicurezza dei partecipanti o l'interpretazione dei risultati dello studio.
- Individui con ipersensibilità o reazione allergica alle proteine di criceto o ad altri componenti dell'intervento dello studio.
- Membri del personale del sito dello sperimentatore direttamente coinvolti nella conduzione dello studio e dei loro familiari, membri del personale del sito altrimenti supervisionati dallo sperimentatore o partecipanti che sono dipendenti Pfizer, compresi i loro familiari, direttamente coinvolti nella conduzione dello studio.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione incrociata
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: PF-06741086
I partecipanti verranno assegnati al trattamento con PF-06741086 dopo una fase di osservazione di 6 mesi sul loro attuale regime di emofilia.
|
Dose da carico di 300 milligrammi (mg) per via sottocutanea (sc) seguita da 150 mg quadrati una volta alla settimana (qw).
300 mg sc qw sono prescritti per i partecipanti che soddisfano i criteri di aumento della dose.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Model-Based Annualized Bleeding Rate (ABR) of Treated Bleeding Events: Inhibitor Cohort (Participants With Prior OD Therapy at OP)
Lasso di tempo: OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
|
ABR is defined as number of bleeding episodes per year.
ABR was calculated as number of bleeds requiring treatments/ (days on treatment period/365.25).
If a participant did not complete a treatment period, days on treatment ended at last dosing date + 6 days.
Treated bleed: If a bleed was treated with factor replacement or bypass agents within 48 hours of start of bleeding, regardless of the type of treatment (preventive, prophylaxis or OD medication).
A model-based ABR using a repeated measures negative binomial model is reported for this outcome measure.
|
OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
|
|
Model-Based ABR of Treated Bleeding Events: Non-Inhibitor Cohort (Participants With Prior OD Therapy at OP)
Lasso di tempo: OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
|
ABR is defined as number of bleeding episodes per year.
ABR was calculated as number of bleeds requiring treatments/ (days on treatment period/365.25).
If a participant did not complete a treatment period, days on treatment ended at last dosing date + 6 days.
Treated bleed: If a bleed was treated with factor replacement or bypass agents within 48 hours of start of bleeding, regardless of the type of treatment (preventive, prophylaxis or OD medication).
A model-based ABR using a repeated measures negative binomial model is reported for this outcome measure.
|
OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
|
|
Model-Based ABR of Treated Bleeding Events: Non-Inhibitor Cohort (Participants With RP at OP)
Lasso di tempo: OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
|
ABR is defined as number of bleeding episodes per year.
ABR was calculated as number of bleeds requiring treatments/ (days on treatment period/365.25).
If a participant did not complete a treatment period, days on treatment ended at last dosing date + 6 days.
Treated bleed: If a bleed was treated with factor replacement or bypass agents within 48 hours of start of bleeding, regardless of the type of treatment (preventive, prophylaxis or OD medication).
A model-based ABR using a repeated measures negative binomial model is reported for this outcome measure.
|
OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
|
|
Number of Participants With Adverse Events (AEs): Inhibitor and Non-Inhibitor Cohort
Lasso di tempo: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
AEs included both serious AEs and all other AEs.
|
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
|
Number of Participants With Serious Adverse Events (SAEs): Inhibitor and Non-Inhibitor Cohort
Lasso di tempo: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
AE: any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
SAE: any untoward medical occurrence at any dose that resulted in any of the following outcomes: death; life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect; or that was considered as an important medical event.
|
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
|
Number of Participants With Thrombotic Events: Inhibitor and Non-Inhibitor Cohort
Lasso di tempo: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
Thrombotic events are when a blood clot (thrombus) forms in a blood vessel in the arm, leg, lung, or head and can be life-threatening.
A thrombus can occur in veins (venous thrombosis) or arteries (arterial thrombosis).
|
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
|
Number of Participants With Thrombotic Microangiopathy: Inhibitor and Non-Inhibitor Cohort
Lasso di tempo: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
Thrombotic microangiopathy: pathological state where micro-vessels are occluded by platelet rich thrombi leading to thrombocytopenia (low platelets) and microangiopathic haemolytic anaemia (red blood cell destruction) and potential end organ damage.
|
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
|
Number of Participants With Disseminated Intravascular Coagulation/ Consumption Coagulopathy: Inhibitor and Non-Inhibitor Cohort
Lasso di tempo: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
Disseminated intravascular coagulation is characterized by widespread clotting in small blood vessels, and consumption of platelets and clotting factors by the clots, leading to bleeding.
|
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
|
Number of Participants With Anti-drug Antibodies (ADA) and Neutralizing Antibodies (NAb) Against PF- 06741086: Inhibitor and Non-Inhibitor Cohort
Lasso di tempo: During prophylaxis treatment in ATP (12 months)
|
ADA positive: A participant with >=1 treatment induced or treatment-boosted ADA response.
NAb positive: An ADA positive participant with >=1 treatment induced or treatment boosted NAb response.
|
During prophylaxis treatment in ATP (12 months)
|
|
Number of Participants With Transient and Persistent ADA and NAb Against PF-06741086: Inhibitor and Non-Inhibitor Cohort
Lasso di tempo: During prophylaxis treatment in ATP (12 months)
|
Persistent ADA: participant with treatment-induced or treatment-boosted ADA detected at 2 or more times during treatment including any follow-up, where first and last ADA positive samples separated by >=16 weeks.
Transient ADA: treatment-induced or treatment-boosted ADA detected at only 1 time during treatment or follow-up.
Persistent NAb: NAb-positive participant with first and last positive NAb samples detected >=16 weeks posttreatment, irrespective of any negative samples in between.
Transient NAb: NAb-positive participant with (1) treatment-induced/treatment-boosted NAb sample detected at only 1 time posttreatment or (2) treatment-induced/treatment-boosted NAb samples detected at 2 or more times where first and last positive samples separated by <16 weeks, and participant's last sample was NAb or ADA negative.
|
During prophylaxis treatment in ATP (12 months)
|
|
Number of Participants With Injection Site Reactions (ISRs): Inhibitor and Non-Inhibitor Cohort
Lasso di tempo: During prophylaxis treatment in ATP (12 months)
|
ISR included: injection site haematoma, injection site pain, injection site bruising, injection site erythema, injection site induration, injection site oedema, Injection site pruritus and Injection site swelling.
ISR graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 where grade 1: tenderness with or without associated symptoms (warmth, erythema, itching), grade 2: pain, lipodystrophy, edema, phlebitis, grade 3: ulceration or necrosis, severe tissue damage, operative intervention indicated, grade 4: life-threatening consequences, urgent intervention indicated and grade 5: death.
In this outcome measure only categories with non-zero values reported.
|
During prophylaxis treatment in ATP (12 months)
|
|
Number of Participants With Clinically Significant Changes in Physical Examinations: Inhibitor and Non-Inhibitor Cohort
Lasso di tempo: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
Physical examination included assessments of the head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems.
Height and weight were also measured and recorded.
Clinical significance in physical examinations was determined by investigator.
|
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
|
Number of Participants With Clinically Significant Changes in Vital Signs: Inhibitor and Non-Inhibitor Cohort
Lasso di tempo: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
Vital signs included temperature, pulse rate, respiratory rate, and blood pressure.
Blood pressure and pulse rate were measured in a supine position using completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions.
Respiratory rate was measured by observing and counting the respirations of the participant for 30 seconds and multiplied by 2. Clinical significance of vital signs was determined by investigator.
|
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
|
Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters: Inhibitor and Non-Inhibitor Cohort
Lasso di tempo: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
Hematology included: hemoglobin; leukocytes; neutrophils; and platelets.
Chemistry included: potassium; aspartate aminotransferase; creatinine; alkaline phosphatase; total bilirubin; albumin; calcium corrected, estimated decreased; sodium; and calcium.
Clinical significance of laboratory parameters was determined by investigator.
|
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
|
Number of Participants With Severe/ Systematic Hypersensitivity and Anaphylactic Reactions: Inhibitor and Non-Inhibitor Cohort
Lasso di tempo: During prophylaxis treatment in ATP (12 months)
|
Systemic hypersensitivity is a complex immune response where the immune system reacts excessively to an antigen, often leading to severe allergic reactions, including widespread symptoms (which may affect multiple organs), such as rash, swelling of your face, lips, mouth, or tongue, trouble breathing, wheezing, dizziness, fainting, fast heartbeat, pounding in your chest or sweating.
Anaphylaxis is a severe, potentially fatal, systemic allergic reaction that occurs suddenly after contact with an allergy causing substance.
|
During prophylaxis treatment in ATP (12 months)
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Model-Based ABR of Joint Bleeds: Inhibitor and Non-Inhibitor Cohort
Lasso di tempo: OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
|
ABR: number of bleeding episodes per year.
ABR was calculated as number of bleeds requiring treatments/ (days on treatment period/365.25).
If a participant did not complete a treatment period, days on treatment ended at last dosing date + 6 days.
Joint bleed: bleeding episode characterized by rapid loss of range of motion as compared with baseline that was associated with any combination of the following: pain or an unusual sensation in the joint, palpable swelling, and warmth of the skin over the joint.
A model-based ABR using a repeated measures negative binomial model is reported for this outcome measure.
|
OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
|
|
Model-Based ABR of Spontaneous Bleeds: Inhibitor and Non-Inhibitor Cohort
Lasso di tempo: OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
|
ABR: number of bleeding episodes per year.
ABR was calculated as the number of bleeds requiring treatments/ (days on treatment period/365.25).
If a participant did not complete a treatment period, the days on treatment ended at the last dosing date + 6 days.
Spontaneous bleed: Bleeding for no apparent/known reason particularly into the joints, muscles, and soft tissues.
A model-based ABR using a repeated measures negative binomial model is reported for this outcome measure.
|
OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
|
|
Model-Based ABR of Target Joint Bleeds: Inhibitor and Non-Inhibitor Cohort
Lasso di tempo: OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
|
ABR: number of bleeding episodes per year.
ABR was calculated as number of bleeds requiring treatments/ (days on treatment period/365.25).
If participant did not complete a treatment period, days on treatment ended at last dosing date + 6 days.
Target joint: a major joint into which repeated bleeds occurred.
Joint bleed: bleeding episode characterized by rapid loss of range of motion as compared with baseline that was associated with any combination of following: pain or unusual sensation in joint, palpable swelling, and warmth of the skin over joint.
A model-based ABR using a repeated measures negative binomial model is reported for this outcome measure.
|
OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
|
|
Model-Based ABR of Total Bleeds: Inhibitor and Non-Inhibitor Cohort
Lasso di tempo: OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
|
ABR: number of bleeding episodes per year.
ABR was calculated as number of bleeds requiring treatments/ (days on treatment period/365.25).
If participant did not complete treatment period, days on treatment ended at last dosing date + 6 days.
Treated bleed: If a bleed was treated with factor replacement or bypass agents within 48 hours of start of bleeding, regardless of the type of treatment (preventive, prophylaxis or on-demand medication).
Untreated bleed: If a bleed was untreated with factor replacement or bypass agents within 48 hours of start of bleeding, regardless of the type of treatment (preventive, prophylaxis or on-demand medication), it was considered as an untreated bleed.
Total bleeds: Treated bleeds + untreated bleeds.
A model-based ABR using a repeated measures negative binomial model is reported for this outcome measure.
|
OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
|
|
Change From Baseline in Hemophilia Joint Health Score (HJHS) at Month 6: Non-Inhibitor Cohort
Lasso di tempo: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
HJHS evaluated total joint score for 6 joints (left ankle, right ankle, left elbow, right elbow, left knee, right knee) and the global gait score.
Joint total score per joint ranged from 0 to 20 (evaluated as: swelling [0-3], duration of swelling [0-1], muscle atrophy [0-2], crepitus on motion [0-2], flexion loss [0-3], extension loss [0-3], joint pain [0-2], and strength [0-4]).
Global gait score ranged from 0 to 4 based on walking, stairs, running, and hopping on 1 leg.
HJHS total score was sum of total joint score for 6 joints (0 to 120) and global gait score (0 to 4).
The total HJHS score ranged from 0 to 124, where higher scores indicated worse joint health.
|
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
|
Change From Baseline in HJHS at Month 6: Inhibitor Cohort
Lasso di tempo: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
HJHS evaluated total joint score for 6 joints (left ankle, right ankle, left elbow, right elbow, left knee, right knee) and the global gait score.
Joint total score per joint ranged from 0 to 20 (evaluated as: swelling [0-3], duration of swelling [0-1], muscle atrophy [0-2], crepitus on motion [0-2], flexion loss [0-3], extension loss [0-3], joint pain [0-2], and strength [0-4]).
Global gait score ranged from 0 to 4 based on walking, stairs, running, and hopping on 1 leg.
HJHS total score was sum of total joint score for 6 joints (0 to 120) and global gait score (0 to 4).
The total HJHS score ranged from 0 to 124, where higher scores indicated worse joint health.
|
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
|
Change From Baseline in Hemophilia Quality of Life Questionnaire for Adults (Haem-A-QoL) Total Score and Physical Health Domain at Month 6: Non-Inhibitor Cohort, Participants >=17 Years
Lasso di tempo: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
Haem-A-QoL assessed health-related quality of life (QoL) in adult participants (>=17 years of age) with hemophilia.
It contained 46 items with 10 domains that assessed health in the following areas: physical health; feelings; view of self; sports and leisure; work and school; dealing with haemophilia; treatment; future; family planning; partnership and sexuality.
All items were based on a 5-point Likert type scale (1= never, 2= rarely, 3= sometimes, 4= often, 5= all the time).
Scoring was performed by averaging non-missing item responses for each domain, then each domain score was rescaled from 0 to 100, lower scores signified higher QoL.
Total Haem-A-QoL score was averaged across the 46 items values and then rescaled from 0 to 100, lower Haem-A-QoL scores signified better QoL.
|
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
|
Change From Baseline in Haem-A-QoL Total Score and Physical Health Domain at Month 6: Inhibitor Cohort, Participants >=17 Years
Lasso di tempo: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
Haem-A-QoL assessed health-related quality of life (QoL) in adult participants (>=17 years of age) with hemophilia.
It contained 46 items with 10 domains that assessed health in the following areas: physical health; feelings; view of self; sports and leisure; work and school; dealing with haemophilia; treatment; future; family planning; partnership and sexuality.
All items were based on a 5-point Likert type scale (1= never, 2= rarely, 3= sometimes, 4= often, 5= all the time).
Scoring was performed by averaging non-missing item responses for each domain, then each domain score was rescaled from 0 to 100, lower scores signified higher QoL.
Total Haem-A-QoL score was averaged across the 46 items values and then rescaled from 0 to 100, lower Haem-A-QoL scores signified better QoL.
|
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
|
Change From Baseline in Hemophilia Quality of Life Questionnaire for Children (Haemo-QoL) Total Score at Month 6: Non-Inhibitor Cohort, Participants 12 to <17 Years
Lasso di tempo: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
Haemo-QoL assessed health-related QoL in adolescent participants (12 to <17 years of age) with hemophilia.
It contains 12 items with 77 domains that assesses health in the following areas: physical health; feelings; attitude/view; family; friends; other people; sport and school; coping/dealing; treatment; perceived support; future and relationship.
All items were based on 5-point Likert type scale (1= never, 2= rarely, 3= sometimes, 4= often, 5= all the time).
Scoring was performed by averaging non-missing item responses for each domain, then rescaled from 0 to 100, lower scores signified higher QoL.
Total Haem-A QoL score was averaged across the 77 items values and then rescaled from 0 to 100, lower Haemo-QoL scores signified better QoL.
|
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
|
Change From Baseline in Haemo-QoL Total Score at Month 6: Inhibitor Cohort, Participants 12 to <17 Years
Lasso di tempo: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
Haemo-QoL assessed health-related QoL in adolescent participants (12 to <17 years of age) with hemophilia.
It contains 12 items with 77 domains that assesses health in the following areas: physical health; feelings; attitude/view; family; friends; other people; sport and school; coping/dealing; treatment; perceived support; future and relationship.
All items were based on 5-point Likert type scale (1= never, 2= rarely, 3= sometimes, 4= often, 5= all the time).
Scoring was performed by averaging non-missing item responses for each domain, then rescaled from 0 to 100, lower scores signified higher QoL.
Total Haem-A QoL score was averaged across the 77 items values and then rescaled from 0 to 100, lower Haemo-QoL scores signified better QoL.
|
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
|
Change From Baseline in Hemophilia Activities List (HAL) Total Score at Month 6: Non-Inhibitor Cohort, Participants >=17 Years
Lasso di tempo: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
The HAL was a multiple domain measure of the impact of hemophilia on functional abilities in adults (>=17 years of age).
The 7 domains of this instrument contained 42 items in total, as follows: lying/sitting/kneeling/standing; lower (leg) functioning; upper (arm) functioning; transportation; self-care; household tasks; and sports/leisure.
Items were rated on 6-point scale 1 (impossible) to 6 (never) that described difficulty due to hemophilia.
HAL total score was sum of all items and scored 42 to 252, which were transformed to 0 - 100, where higher scores indicated better functional status.
|
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
|
Change From Baseline in HAL Total Score at Month 6: Inhibitor Cohort, Participants >=17 Years
Lasso di tempo: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
The HAL was a multiple domain measure of the impact of hemophilia on functional abilities in adults (>=17 years of age).
The 7 domains of this instrument contained 42 items in total, as follows: lying/sitting/kneeling/standing; lower (leg) functioning; upper (arm) functioning; transportation; self-care; household tasks; and sports/leisure.
Items were rated on 6-point scale 1 (impossible) to 6 (never) that described difficulty due to hemophilia.
HAL total score was sum of all items and scored 42 to 252, which were transformed to 0 - 100, where higher scores indicated better functional status.
|
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
|
Change From Baseline in Pediatric Hemophilia Activities List (pedHAL) Total Score at Month 6: Non-Inhibitor Cohort, Participants 12 to <17 Years
Lasso di tempo: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
The pedHAL was a multiple domain measure of the impact of hemophilia on functional abilities in adolescents (12 to <17 years of age).
The 7 domains of this instrument contained 53 items in total, as follows: sitting/kneeling/standing; functions of the legs; functions of the arms; use of transportation; self-care; household tasks; leisure activities and sports.
Items were rated on 6-point scale 1 (impossible) to 6 (never) that described difficulty due to hemophilia.
pedHAL total score was normalized in a range of 0 - 100, where higher scores indicated better functional status.
|
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
|
Change From Baseline in pedHAL Total Score at Month 6: Inhibitor Cohort, Participants 12 to <17 Years
Lasso di tempo: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
The pedHAL was a multiple domain measure of the impact of hemophilia on functional abilities in adolescents (12 to <17 years of age).
The 7 domains of this instrument contained 53 items in total, as follows: sitting/kneeling/standing; functions of the legs; functions of the arms; use of transportation; self-care; household tasks; leisure activities and sports.
Items were rated on 6-point scale 1 (impossible) to 6 (never) that described difficulty due to hemophilia.
pedHAL total score was normalized in a range of 0 - 100, where higher scores indicated better functional status.
|
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
|
Patient Global Impression of Change-Hemophilia (PGIC-H) at Month 6: Non-Inhibitor Cohort
Lasso di tempo: Month 6
|
The PGIC-H was a single item assessment of the participant's overall impression of change in their life with hemophilia, on a 7-point scale (1= greatly improved to 7= greatly worsened, where lower scores indicated better improvement).
|
Month 6
|
|
PGIC-H at Month 6: Inhibitor Cohort
Lasso di tempo: Month 6
|
The PGIC-H was a single item assessment of the participant's overall impression of change in their life with hemophilia, on a 7-point scale (1= greatly improved to 7= greatly worsened, where lower scores indicated better improvement).
|
Month 6
|
|
Change From Baseline in EuroQol 5 Dimensions 5 Level (EQ-5D-5L) Index and VAS Scores at Month 6: Non-Inhibitor Cohort
Lasso di tempo: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
EQ-5D-5L consisted of participant completed questionnaire with 2 components: health state profile index and visual analogue scale (VAS).
EQ-5D health state profile index has 5 domains (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), with 5 levels (1= no problems, 2= slight problems, 3= moderate problems, 4= severe problems, 5= extreme problems).
Responses to 5 dimensions comprised health state index value.
E.g. if a participant responds "no problems" for each 5 dimensions, then health state was coded as "11111" with predefined index value to it.
EQ-5D-5L index score ranged from -0.594 to 1, United Kingdom look-up value was applied to all participants, higher scores indicated better health states.
The EQ- VAS measured participant's self-rated health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state) by VAS, where higher scores indicated better heath states.
|
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
|
Change From Baseline in EQ-5D-5L Index and VAS Scores at Month 6: Inhibitor Cohort
Lasso di tempo: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
EQ-5D-5L consisted of participant completed questionnaire with 2 components: health state profile index and visual analogue scale (VAS).
EQ-5D health state profile index has 5 domains (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), with 5 levels (1= no problems, 2= slight problems, 3= moderate problems, 4= severe problems, 5= extreme problems).
Responses to 5 dimensions comprised health state index value.
E.g. if a participant responds "no problems" for each 5 dimensions, then health state was coded as "11111" with predefined index value to it.
EQ-5D-5L index score ranged from -0.594 to 1, United Kingdom look-up value was applied to all participants, higher scores indicated better health states.
The EQ- VAS measured participant's self-rated health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state) by VAS, where higher scores indicated better heath states.
|
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Direttore dello studio: Pfizer CT.gov Call Center, Pfizer
Pubblicazioni e link utili
Pubblicazioni generali
- Matino D, Acharya SS, Taylor CT, Sun P, Agathon D, Raje S, Gould T, Palladino A, Mahlangu J, Lissitchkov T, Todorova M, Chan A, Carcao M, Sun J, Yang R, Wu R, Jin C, Zeng X, Boban A, Bilic E, Frenzel L, Fung Chan GC, Kong Li C, Apte S, Choraria N, Chistolini A, Marchesini E, Peyvandi F, Fujii T, Matsushita T, Kaneda M, Lyu CJ, Park YS, Kim S, Martinez LV, Adrian JM, Wali Y, Al Khabori M, Kurtov I, Alzahrani H, Zaher G, Micic D, Miljic P, Kostic G, Vucic M, Djurdjevic P, Hidalgo OB, Porras JG, Jimenez-Yuste V, Calvo Villas JM, Lopez Fernandez MF, Albayrak C, Okan V, Balkan C, Sahin F, Antmen A, Unal E, Visweshwar N, Sharathkumar A, Kruse-Jarres R. Efficacy and safety of marstacimab prophylaxis in hemophilia A/B with inhibitors: results from the phase 3 BASIS trial. Blood. 2026 Feb 26;147(9):920-931. doi: 10.1182/blood.2025031065.
- Matino D, Palladino A, Taylor CT, Hwang E, Raje S, Nayak S, McDonald R, Acharya SS, Mahlangu J, Jimenez-Yuste V, Choraria N, Yang R, Li CK, Al-Khabori M, Wali Y, Morales Adrian J, Park YS, Zulfikar OB, Teeter J. Marstacimab prophylaxis in hemophilia A/B without inhibitors: results from the phase 3 BASIS trial. Blood. 2025 Oct 2;146(14):1654-1663. doi: 10.1182/blood.2024027468.
Collegamenti utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Effettivo)
Completamento primario
Completamento dello studio (Effettivo)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Processi patologici
- Malattie genetiche, congenite
- Malattie ematologiche
- Disturbi della coagulazione del sangue
- Disturbi emorragici
- Malattie genetiche, legate all'X
- Disturbi della coagulazione del sangue, ereditari
- Disturbi delle proteine della coagulazione
- Malattie e anomalie congenite, ereditarie e neonatali
- Condizioni patologiche, segni e sintomi
- Malattie emiche e linfatiche
- Emofilia A
- Emorragia
- Emofilia B
- Marstacimab
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- B7841005
- 2018-003660-31 (Numero EudraCT)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .